Mycosis Fungoides News

Remetinostat's Promising Results in Mycosis Fungoides Patients Presented at EORTC Meeting - Lymphoma News Today



Remetinostat's Promising Results in Mycosis Fungoides Patients Presented at EORTC Meeting 
Lymphoma News Today
Topical remetinostat 1% gel can significantly reduce the severity of skin lesions and itching in mycosis fungoides (MF) patients without systemic adverse events, data from a Phase 2 trial show. The trial results were presented at the European ...

 


miRagen Therapeutics presents new clinical data from MRG-106 on mycosis fungoides; shares ahead 11% premarket - Seeking Alpha



miRagen Therapeutics presents new clinical data from MRG-106 on mycosis fungoides; shares ahead 11% premarket 
Seeking Alpha
miRagen Therapeutics (NASDAQ:MGEN) announces new interim results from its ongoing Phase 1 clinical trial evaluating the safety, efficacy and pharmacokinetics of MRG-106 in patients with the mycosis fungoides form of cutaneous T-cell lymphoma (CTCL) ...
miRagen (MGEN) Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 ... StreetInsider.com
Remetinostat Phase II Data Demonstrate Efficacy on Skin Lesions, Reduction of Itching and High Tolerability in ... PR Newswire (press release)

all 4 news articles » 


INNATE PHARMA : IPH4102: Final results of the dose-escalation part of the Phase I study - Nasdaq



INNATE PHARMA : IPH4102: Final results of the dose-escalation part of the Phase I study 
Nasdaq
The cohort expansion part is accruing 2 cohorts of 15 patients each in 2 CTCL subtypes (SÚzary syndrome and transformed mycosis fungoides) receiving IPH4102 at the RP2D of 750 mg (fixed dose equivalent to 10 mg/kg) until progression. The primary ...

and more » 


Mycosis Fungoides Global API Phase III Drugs Landscape, 2017 - Medgadget (blog)



Mycosis Fungoides Global API Phase III Drugs Landscape, 2017 
Medgadget (blog)
Mycosis Fungoides- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for ...

and more » 


Mycosis Fungoides Market Analysis 2017 to 2025 - Medgadget (blog)



Mycosis Fungoides Market Analysis 2017 to 2025 
Medgadget (blog)
Mycosis Fungoides- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for ...

and more » 


Skin-Directed Tactics Optimal for Early Cutaneous Lymphoma - Medscape



Medscape
 
Skin-Directed Tactics Optimal for Early Cutaneous Lymphoma 
Medscape
Typical survival for patients diagnosed with stage IA to IIA mycosis fungoides is 10 to 35 years, but more than one-quarter of patients progress to advanced disease, with a median survival of less than 4 years. Early-stage disease often presents with ...

 


Trillium Therapeutics' TTI-621 Program Featured at the EORTC ... - Marketwired (press release)



Trillium Therapeutics' TTI-621 Program Featured at the EORTC ... 
Marketwired (press release)
TORONTO, ONTARIO--(Marketwired - Oct. 16, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company ...

and more » 


Clinical Trial Evaluating Resminostat as Maintenance Therapy in CTCL Is Enrolling Participants - Lymphoma News Today



Lymphoma News Today
 
Clinical Trial Evaluating Resminostat as Maintenance Therapy in CTCL Is Enrolling Participants 
Lymphoma News Today
The RESMAIN study (NCT02953301) is being conducted at about 50 clinical centers in 10 European countries, and is expected to include roughly 150 adult patients with advanced stage mycosis fungoides or SÚzary syndrome ? two CTCL subtypes.

 


28 Stocks Moving In Friday's Pre-Market Session | Benzinga - Benzinga



28 Stocks Moving In Friday's Pre-Market Session | Benzinga 
Benzinga
Inotek Pharmaceuticals Corp (NASDAQ: ITEK) rose 28.5 percent to $3.79 in pre-market trading after the company reported filing of preliminary proxy statement ...
35 Stocks Moving In Friday's Mid-Day Session - Stockhouse Stockhouse

all 2 news articles » 


ETF Preview: ETFs, Futures Positive Pre-Bell Following CPI, Retail ... - Nasdaq



Nasdaq
 
ETF Preview: ETFs, Futures Positive Pre-Bell Following CPI, Retail ... 
Nasdaq
Active broad-market exchange-traded funds ahead of Friday's regular session: SPDR Select Sector Fund - Financial ( XLF ): -0.04% SPDR S&P 500 (.

and more »